GlassScriptPhysician profile
Alexander Mauskop
NPI 1962629147
$581,308.39
in general payments reported to CMS, 2019-2025
30 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145K · 2020: $115K · 2021: $109K · 2022: $93K · 2023: $54K · 2024: $35K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Honoraria: $49K · Food and Beverage: $7,967 · Travel and Lodging: $6,174 · Consulting Fee: $5,596 · Education: $81.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,800.00 |
| Honoraria | $49,400.00 |
| Food and Beverage | $7,967.34 |
| Travel and Lodging | $6,173.50 |
| Consulting Fee | $5,596.25 |
| Education | $81.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $156,949.70 | 2019-2021 | |
| Abbvie INC. | $124,164.08 | 2021-2025 | |
| Lilly USA, LLC | $103,325.76 | 2019-2023 | Reyvow, Emgality, Amyvid |
| Lundbeck LLC | $80,867.99 | 2021-2025 | Vyepti |
| Amgen INC. | $66,128.19 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $34,587.64 | 2019-2025 | |
| Pfizer INC. | $5,652.44 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,620.12 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $1,574.23 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $1,500.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $1,126.23 | 2019 | |
| Upsher-Smith Laboratories LLC | $601.66 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $504.33 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $285.81 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $275.49 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $272.10 | 2019-2020 | |
| Axogen | $204.36 | 2023 | Avance Nerve Graft |
| Boston Scientific Corporation | $159.50 | 2019 | |
| Revance Therapeutics, INC. | $116.63 | 2025 | Daxxify |
| Idorsia Pharmaceuticals US INC | $77.25 | 2023 | Quviviq |
| Scilex Pharmaceuticals INC. | $64.21 | 2023-2025 | Ztlido |
| Zyla Life Sciences, INC. | $52.64 | 2019-2020 | |
| Novo Nordisk INC | $46.40 | 2023 | |
| Medtronic Vascular, INC. | $36.06 | 2019 | |
| Currax Pharmaceuticals LLC | $29.78 | 2022-2023 | Onzetra Xsail |
| Endo Pharmaceuticals INC. | $22.14 | 2019 | |
| Bausch Health US, LLC | $19.82 | 2019 | |
| Tonix Medicines, INC. | $17.86 | 2025 | Zembrace Symtouch |
| Impel Pharmaceuticals LLC | $16.08 | 2025 | Trudhesa |
| Collegium Pharmaceutical, INC. | $9.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Mauskop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.